Table 1 Baseline clinical characteristics of participants from GHS-prospective design, NHS and HPFS cohorts
| Â | GHS-prospective design | HPFS | NHS | |
|---|---|---|---|---|
|  | Men (n = 242) | Women (n = 117) | Men (n = 833) | Women (n = 902) |
Age (years) | 63.6 ± 8.3 | 66.1 ± 7.5 | 63.6 ± 8.6 | 59.1 ± 7.2 |
Current Smokers (%) | 55 (22.7) | 9 (7.7) | 56 (6.7) | 123 (13.6) |
Diabetes duration (years) | 12.9 ± 8.8 | 15.7 ± 9.8 | 7.8 ± 9.6 | 11.0 ± 9.3 |
BMI (kg/m2) | 29.4 ± 4.3 | 31.8 ± 5.4 | 27.8 ± 4.6 | 29.7 ± 6.3 |
HbA1C % (mmol/mol) | 8.6 ± 1.9 (70 ± 20.8) | 8.7 ± 1.8 (72 ± 19.7) | 7.3 ± 1.5 (56 ± 16.4) | 7.1 ± 1.8 (54 ± 19.7) |
Total cholesterol (mg/dl) | 175.4 ± 46.0 | 176.7 ± 45.3 | 209.6 ± 40.4 | 229.6 ± 45.4 |
HDL-cholesterol (mg/dL) | 42.2 ± 14.2 | 46.4 ± 15.0 | 40.2 ± 11.1 | 51.7 ± 15.9 |
Triglycerides (mg/dL) | 158.5 ± 98.8 | 140.3 ± 74.3 | 191.0 ± 101.7 | 208.9 ± 152.4 |
hsCRP (mg/L) | 6.7 ± 14.3 | 4.9 ± 8.3 | 3.2 + 5.4 | 7.9 ± 8.8 |
Anti-diabetic therapy (%) | 126 (52.0) | 68 (58.1) | 603 (72.4) | 493 (54.7) |
Hypertension (%) | 198 (81.8) | 107 (91.5) | 393 (47.2) | 599 (66.4) |